Analyst firms · Morgan Stanley · MRVI

Morgan Stanley MRVI price target and rating history

Maravai LifeSciences Holdings Inc. (MRVI) · Health Care

Morgan Stanley rates Maravai LifeSciences Holdings Inc. (MRVI) Equal-Weight with a $10 price target, as of its latest action on Aug 13, 2024. It has published 3 rating actions on MRVI since August 2021, including 0 upgrades and 1 downgrade.

Current rating
Equal-Weight
Price target
$10
Median target, all firms
Too few
Actions on MRVI
3

Morgan Stanley price target on MRVI

$12$11$1020222023202420252026
Morgan Stanley price target on MRVI, each point a stated target, August 2021 to August 2024. Targets before August 2024 (divided by 5) are adjusted for a stock split, going by the prior target Morgan Stanley restated.

Every Morgan Stanley rating on MRVI

How other firms rate MRVI

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
KeyBanc Capital MarketsOverweight$11Nov 12, 2026
TD CowenBuy$9Oct 5, 2026

Questions about Morgan Stanley and MRVI

What is Morgan Stanley's price target for MRVI?
Morgan Stanley's latest stated price target for Maravai LifeSciences Holdings Inc. (MRVI) is $10, from its action on Aug 13, 2024.
What is Morgan Stanley's rating on MRVI?
Morgan Stanley rates MRVI Equal-Weight, a neutral rating, as of Aug 13, 2024.
When did Morgan Stanley last change its view on MRVI?
On Aug 13, 2024, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $11 to $10.

More MRVI rating histories

All Morgan Stanley ratingsMRVI news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.